Second artificial heart implant due in 'weeks'

March 17, 2014
A picture taken on December 21, 2013 at Georges Pompidou European hospital in Paris, shows an artificial heart produced by Biomedical firm Carmat

After its first recipient died, French biomedical firm Carmat said on Monday it expected to try again to implant its experimental artificial heart in another patient "in several weeks".

Artificial hearts have been in use for many years as a temporary fix for patients with chronic heart problems, but the Carmat product aims to provide a longer-term solution to enable hospitalised patients to return home and lead normal lives.

Philippe Pouletty, Carmat co-founder, told Europe 1 radio that a second experiment would depend on finding a suitable patient, adding that the company still had to wait for the results of an in-depth analysis of the first trial on a 76-year-old man.

The septuagenarian with terminal died on March 2, two-and-a-half months after being implanted with the artificial device.

"Currently we don't know what the patient's cause of death is, we are doing in-depth analyses before going on to the next implant," Pouletty said, appearing to refute a theory that a short circuit caused the device to stop working.

The company is hoping to trial the in a total of four , and if all survive for at least one month, the experiment will be deemed a success.

Graphic presenting the artificial heart developed by French firm Carmat

The device, a self-contained unit implanted in a patient's chest, is a mix of synthetic materials and animal tissue, and seeks to mimic the form and function of an actual human heart.

In that sense, it varies greatly from other artificial hearts currently being used, which are cruder, mostly synthetic pumps.

Nearly 100,000 people in Europe and the United States are in need of a transplant, according to Carmat.

Explore further: Artificial heart with Norwegian sensor

Related Stories

French firm starts human trials of artificial heart

December 20, 2013

French biomedical firm Carmat said on Friday it had begun the first human trial of its prototype artificial heart, which aims at overcoming shortages of organs available for transplant.

Recommended for you

No new heart muscle cells in mice after the newborn period

November 5, 2015

A new study from Sweden's Karolinska Institutet shows that new heart muscle cells in mice are mainly formed directly after birth. After the neonatal period the number of heart muscle cells does not change, and A new study ...

Nanotechnology could spur new heart treatment

October 29, 2015

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.